Department of Clinical Microbiology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo, Japan.
Department of Dermatology, Toranomon Hospital, Tokyo, Japan.
J Dermatol. 2021 Sep;48(9):1365-1371. doi: 10.1111/1346-8138.15940. Epub 2021 May 17.
The prevalence of antimicrobial-resistant Cutibacterium acnes is an important concern for the antimicrobial treatment of acne vulgaris. We hypothesized that antimicrobial treatment regimens for acne vulgaris would change following the revisions in the Japanese acne treatment guidelines, which added a statement regarding appropriate antimicrobial usage. Here, we studied the changes in antimicrobial use and antimicrobial-resistant C. acnes isolated from acne patients. A total of 127 C. acnes isolates collected from 212 patients with acne between 2013 and 2018 were used. Roxithromycin and clindamycin resistance rates were approximately 50% and 40%, respectively. In contrast, the prevalence of low doxycycline-susceptible strains (minimum inhibitory concentration [MIC] ≥8 μg/mL) in 2018 (17.4%) was 5.6-fold higher than that in 2013 (3.1%). Although the number of patients with severe and moderate acne did not change, the number of patients with a history of oral tetracycline use increased. The incidence of low doxycycline-susceptible strains was high in patients with a history of oral tetracycline use. The prevalence of strains with a 16S rRNA mutation, which confers reduced susceptibility to tetracyclines, increased by 8.6-fold (12.1%) from 2016 to 2018 in comparison with the previously revised guidelines (1.4%). Furthermore, the prevalence of low susceptibility strains with two resistance factors, 16S rRNA mutation and ribosomal S10 protein substitution, also increased. Approximately 10% of strains had the exogenous resistance gene, tet(W) (2013 to 2015, 10.1%; 2016 to 2018, 8.6%), and these strains showed different susceptibility to doxycycline dependent on the expression of tet(W) (MIC range 0.5-8 μg/mL). Our data show that the antimicrobial resistance pattern in C. acnes changes according to the trend of antimicrobial usage for acne treatment. Therefore, we should pay heed to the rapid dissemination of tetracycline resistance in C. acnes owing to acquisition of 16S rRNA mutation and tet(W).
痤疮丙酸杆菌对抗菌药物的耐药性是寻常痤疮抗菌治疗的一个重要关注点。我们假设,随着日本痤疮治疗指南的修订,添加了关于适当使用抗菌药物的声明,寻常痤疮的抗菌治疗方案将会发生变化。在这里,我们研究了痤疮患者使用的抗菌药物和分离的痤疮丙酸杆菌对抗菌药物的耐药性变化。共使用了 2013 年至 2018 年间从 212 名痤疮患者中收集的 127 株痤疮丙酸杆菌分离株。罗红霉素和克林霉素的耐药率分别约为 50%和 40%。相比之下,2018 年(17.4%)低剂量多西环素敏感菌株(最低抑菌浓度[MIC]≥8μg/ml)的流行率是 2013 年(3.1%)的 5.6 倍。尽管严重和中度痤疮患者的数量没有变化,但有口服四环素使用史的患者数量有所增加。有口服四环素使用史的患者中低剂量多西环素敏感菌株的发生率较高。与之前修订的指南相比,2016 年至 2018 年,16S rRNA 突变导致对四环素敏感性降低的菌株的发生率增加了 8.6 倍(12.1%)。此外,同时具有 16S rRNA 突变和核糖体 S10 蛋白取代这两种耐药因子的低敏感性菌株的流行率也有所增加。大约 10%的菌株具有外源性耐药基因 tet(W)(2013 年至 2015 年为 10.1%,2016 年至 2018 年为 8.6%),这些菌株对多西环素的敏感性因 tet(W)的表达而不同(MIC 范围为 0.5-8μg/ml)。我们的数据表明,痤疮丙酸杆菌对抗菌药物的耐药模式会根据痤疮治疗中抗菌药物使用的趋势而变化。因此,我们应该注意由于获得 16S rRNA 突变和 tet(W)而导致的痤疮丙酸杆菌中四环素耐药性的快速传播。